Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Abstract: Reconfigurable arrays enable flexible utilization of system resources and thus become a key technology in modern radar and communication systems. Once the array is reconfigured, its steering ...

Neutral-atom arrays are a rapidly emerging platform to create quantum computers. In a foundational study led by graduate students Aaron Holman and Yuan Xu from the Will and Yu labs, respectively, the ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Selling the stake in REV102 frees RallyBio up to focus on the C5 inhibitor RLYB116. (NWM/iStock/Getty Images Plus) Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 ...

Method references are a shorthand way to write lambda expressions that call a single method. Rather than implementing a method in a functional interface, a method reference simply points to an ...